February 21, 2017
Nativis Rounds Out Board of Directors with Appointment of Dr. Una Ryan
Nativis Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Dr. Una Ryan has been appointed to its board of directors effective immediately.
Ryan is a biologist and seasoned healthcare executive with extensive experience serving on the boards of public, private and non-profit companies. She is currently a limited partner at Breakout Ventures, Managing Director of Golden Seeds, an investment firm empowering women entrepreneurs, and a partner in Astia Angel, investing in women-led ventures. Ryan currently serves on the boards of AMRI, a global contract research and manufacturing company and RenovoRx, a medical device company. She was previously the President and CEO at Diagnostics for All, Inc., a developer of inexpensive diagnostic tools for global health and agriculture; Waltham Technologies, a cleantech start-up; and AVANT Immunotherapeutics Inc. (now Celldex), a company developing vaccines for cancer and global health. Throughout her career, Ryan has successfully translated science into successful businesses, driving growth and overseeing multiple M&A’s in order to create robust and diverse organizations.
Ryan spent more than 20 years as a Professor of Medicine at the University of Miami, Washington University, St. Louis and Boston University where she conducted research on vascular biology. She holds a Ph.D. in Cellular and Molecular Biology from University of Cambridge and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. She received an Honorary Doctor of Science degree from Bristol University in 2009.
“We are thrilled to be able to continue to diversify our board of directors and welcome Una, a distinguished entrepreneur, biologist and healthcare executive,” said Nativis CEO Chris Rivera. “Una brings a broad range of experience in the life science and investment arenas to the board, and her insight will be of great value to Nativis as we continue to develop and seek long term partners for of our novel ulRFE technology. Una’s background in global health and developing medical technologies adds significantly to the diversity of our other Directors’ extensive industry experience, which includes, for example; cyber-security, disruptive technologies, financial management, venture capital and bio-pharmaceutical development.”
Ryan added, “I am excited to join the Nativis team, and look forward to helping guide the company through the development of its unique technology platform. Nativis’ ulRFE technology represents an unprecedented opportunity to advance a new wave of treatment for recurrent glioblastoma multiforme and other health care indications, and I believe that with the right resources and strategies, the company can position itself for future success.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE™) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.
Investor Relations Contact:
Lee Roth / Tram Bui
email@example.com / firstname.lastname@example.org
646-536-7012 / 7035
Media Relations Contact:
Aaron Blank / Amber Benson